Gauge, pain and flow rate

The risk of a long needle is not that it hurts more, though it does. It is that in a lean thigh or arm it can pass through the subcutaneous layer entirely and deliver into muscle. Intramuscular delivery of a preparation designed for subcutaneous absorption produces faster and more variable uptake; the insulin literature documented this decades ago with unambiguous pharmacokinetic consequences. For a weekly acylated peptide the effect on a single dose is less dramatic than for a mealtime insulin, but it is still an unintended change in the input function, and it is entirely avoidable.

Barrel size and graduation interval

U-100 insulin syringes are commonly supplied in three barrel sizes. The 0.3 mL barrel holds thirty units and is usually graduated in single units, with some products marked in half units. The 0.5 mL barrel holds fifty units and is generally marked in single units. The 1 mL barrel holds one hundred units and is very often marked in two-unit increments, because a hundred legible single marks will not fit on a barrel of that length.

The practical consequence is direct. A person accustomed to counting single marks on a 0.5 mL barrel who switches to a 1 mL barrel and counts the same number of marks will draw twice the intended volume. The reverse switch halves it. Nothing about the appearance of the syringe warns of this; only the printed numerals do, and they are small.

The general rule that follows is to choose the smallest barrel that comfortably holds the intended volume, both for graduation resolution and because a small volume measured near the bottom of a large barrel is the least accurate configuration available. Where a dose is genuinely small — a few units — a half-unit-graduated 0.3 mL barrel is the only presentation that offers meaningful resolution.

Dead space, air and the dose that stays behind

Dead space is the volume held in the needle and hub after the plunger has bottomed out. For a fixed-needle insulin syringe it is very small, of the order of two to seven microlitres. For a detachable needle on a conventional luer fitting it is considerably larger, sometimes exceeding fifty microlitres.

Whether that matters is a question of proportion. At an intended volume of two hundred microlitres, a five-microlitre loss is under three per cent and irrelevant. At an intended volume of twenty microlitres — which a concentrated reconstitution produces — the same loss is a quarter of the dose. This is one of the strongest practical arguments against making a vial up to a very high concentration: it pushes the injection volume down into the range where fixed losses dominate.

Air bubbles interact with the same arithmetic. A bubble displaces solution, so a barrel drawn to eight units containing a one-unit bubble delivers seven units of drug. Small bubbles in a subcutaneous injection are not a safety problem in the way they would be intravenously; they are a dosing problem. Expelling them by tapping the barrel upright and pushing the plunger to the mark is a volumetric correction, not a ritual, and it matters most at exactly the small volumes where people are least inclined to bother.

Common vial strengths, worked

For a 2 mg vial: 1.0 mL of diluent gives 2 mg/mL and 20 micrograms per unit; 2.0 mL gives 1 mg/mL and 10 micrograms per unit. For a 5 mg vial: 1.0 mL gives 50 micrograms per unit; 2.0 mL gives 25; 2.5 mL gives 20. For a 10 mg vial: 1.0 mL gives 100 micrograms per unit; 2.0 mL gives 50; 5.0 mL gives 20.

Reading in the other direction: at 50 micrograms per unit, a 250 microgram dose is five units, a 500 microgram dose is ten, a 1 mg dose is twenty. At 100 micrograms per unit those become two and a half, five and ten. The half unit in that first case is not measurable on a barrel graduated in single units, which is a small illustration of how concentration choice constrains what doses can actually be given.

The general principle is to choose a diluent volume that puts your intended doses on whole, comfortably readable graduations across the whole escalation range you expect to use, and then to leave it alone. Choosing a concentration that makes the current dose convenient and the next three doses awkward is a common and avoidable annoyance.¹

Needle length and the two millimetres that matter

Ultrasound measurement across large adult populations puts skin thickness at the four standard injection sites at roughly 1.9 to 2.4 millimetres, with surprisingly little variation by body mass index, sex or ethnicity. Subcutaneous fat thickness varies by a factor of many; the layer above it barely varies at all.²

That finding is why needle-length recommendations moved decisively toward short needles. A 4 mm needle inserted perpendicular clears the dermis in essentially all adults and deposits into subcutaneous tissue, and comparative trials of 4 mm pen needles found glycaemic control and safety equivalent to longer needles with better patient ratings.³ The published injection-technique recommendations that followed endorse 4 mm as adequate for adults regardless of body size.⁴

The persistence of 12.7 mm needles in the research-peptide market is therefore habit rather than reasoning, and it is not a harmless habit. A longer needle in a lean thigh or arm can traverse the subcutaneous layer and deliver intramuscularly, which changes the absorption profile of a preparation designed as a subcutaneous depot. The correct response to uncertainty about depth is a shorter needle, not a longer one.

Gauge, angle and whether to pinch

Gauge describes bore: higher numbers are thinner. Insulin syringes are commonly twenty-nine to thirty-one gauge and pen needles run to thirty-two or thirty-four. Thinner needles are more comfortable and flow more slowly. For an aqueous peptide solution the flow penalty is minor; for anything viscous it becomes real, and the practical failure is that people push harder and lose control of the plunger.

Angle and skin-pinch technique follow from length. With a 4 mm needle, insertion perpendicular to the skin without a pinch is appropriate, because there is no plausible way to reach muscle. With longer needles a lifted skin fold is required in order to raise the subcutaneous layer away from muscle, and the fold must be released only after the needle is withdrawn — releasing early while the needle is in situ defeats the purpose.⁴

The habit of injecting at forty-five degrees is a legacy of long needles and is a poor default with short ones, because an oblique 4 mm track can end intradermally. The Journal states the simple version: short needle, ninety degrees, no pinch, and there is then very little left to get wrong about depth.

Accidental intramuscular delivery

Intramuscular delivery of a subcutaneous preparation accelerates and destabilises absorption. The insulin literature established this cleanly: intramuscular administration produces faster onset and markedly greater between-occasion variability than subcutaneous administration of the same preparation.⁵

For a weekly acylated agonist the consequences of one such injection are less acute than for a mealtime insulin, because the depot is designed to release over days and albumin binding dominates the kinetics. It is nonetheless an unintended change in the input function, and where it happens repeatedly — a long needle used consistently in a lean thigh — it becomes a persistent alteration in exposure that no dose adjustment will explain.

The signals are not reliable. A deeper ache during and after injection, more bleeding, and a sensation of the injection being harder to push are all suggestive and none are diagnostic. This is why the answer is structural rather than perceptual: a 4 mm needle removes the possibility, and no amount of attentiveness makes a 12.7 mm needle in a lean thigh safe from it.

Why site matters less in this class than in insulin

Insulin absorption differs by site, which is why insulin regimens specify them. For the long-acting acylated incretin agonists, the labelling treats abdomen, thigh and upper arm as interchangeable, and the clinical pharmacokinetic literature reflects site comparisons conducted during development.⁶

The mechanistic reason is straightforward. These molecules are engineered to bind albumin reversibly and to release slowly from a subcutaneous depot; that release, and not regional blood flow, is the rate-limiting step. Where the depot sits therefore matters much less than it does for a preparation whose absorption is perfusion-limited.

This is a genuine practical simplification and it should be said clearly, because rotation advice imported wholesale from insulin practice can leave people believing that changing region will change their exposure. Rotation in this class is about protecting tissue from repeated trauma. It is not a dose-control measure, and a person who injects the thigh one week and the abdomen the next has not altered their treatment.

The exception is tissue that has already changed. Once lipohypertrophy is established, absorption from that area is unpredictable regardless of molecule, and the interchangeability above no longer applies.

The arithmetic is only as good as the label

Every calculation above starts from a stated mass of peptide in the vial. For licensed product that figure is a release specification. For research-grade lyophilised powder it is a claim, and the difference matters because the claim sits at the front of every subsequent computation.

Two distinct quantities are involved. Chromatographic purity is the proportion of peptide-related material that is the intended peptide. Peptide content is the fraction of the vial mass that is peptide at all, the remainder being counter-ions, residual solvent, water and excipient. A vial can be ninety-nine per cent pure and contain materially less peptide than labelled, and content is the number that determines a dose.

The four independent services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — report purity routinely and content less consistently. Several vendors, among them WXT, SSA, CPC, SWB and MKM, publish per-batch reports; others publish nothing verifiable. Where content has not been measured, the labelled mass should be treated as an upper bound and the resulting dose figure as an estimate. That is unsatisfying and it is honest, and it is why the Journal has argued in Analytics for content and endotoxin as standard reported fields.

How the Journal reports technique

Two bodies of evidence underlie this file. Questions of tissue, depth, needle length and rotation come from the insulin injection-technique literature, which is large, well conducted and directly transferable because it concerns anatomy rather than any particular molecule. Questions of absorption by site, in-use stability and exposure come from the incretin literature, which is smaller and where we say so. Where we describe practice rather than evidence, the text states it.

We give arithmetic in full rather than in tables of pre-computed unit counts, deliberately. A pre-computed table is correct only for the concentration it was computed for, and the recurring error in this market is precisely the reuse of a correct number under changed conditions. A reader who can perform the four-line calculation is protected against a class of error that no table can prevent.

Nothing in this file is medical advice. The Journal does not recommend doses, products, diluents or suppliers, and cannot assess an individual. Several compounds discussed are sold for research use only, are not approved for human use in any jurisdiction, and are not manufactured or released to any human sterility, content or endotoxin standard. Injection technique is properly taught in person by a clinician or nurse, and this file is not a substitute for that.

A short glossary

Unit (U-100): ten microlitres. A volume, not an amount of drug. Concentration: mass per volume, here usually milligrams per millilitre. Dead space: volume retained in needle and hub after full depression of the plunger. Priming: expelling a small volume before dosing, to clear air and confirm flow.

Gauge: needle bore, inversely numbered — higher gauge is thinner. Subcutaneous: into the fat layer beneath the dermis. Intradermal: within the skin itself, which is what an oblique short needle risks. Intramuscular: into muscle beneath the subcutaneous layer.

Lipohypertrophy: thickened subcutaneous tissue from repeated injection, with blunted and variable absorption. Lipoatrophy: localised loss of subcutaneous fat, a different and now rare immune-mediated phenomenon. Bacteriostatic: inhibiting microbial growth, not sterilising. In-use period: the interval after first puncture during which a product remains within specification, established by stability testing.

The distinction between bacteriostatic and sterile, and the distinction between purity and content, account between them for a large share of the confused correspondence this desk receives.

Four things about this that are genuinely unestablished

First, the in-use stability of home-reconstituted peptides. No sequence-specific, buffer-specific, container-specific stability study exists for the great majority of what is sold in this market, and the figures in circulation are extrapolations.

Second, whether the injection-site interchangeability established for licensed acylated agonists holds for material of uncertain formulation. The mechanism suggests it should; nobody has measured it.

Third, the real-world frequency of the errors catalogued above. Our ranking comes from correspondence, which is a self-selected sample that over-represents people who noticed. The denominator is unknown.

Fourth, whether any of the technique measures described here changes outcomes in this specific population. They are supported by anatomical evidence and by the insulin literature; a trial in incretin users has not been done and probably will not be.⁴

Readers who know of stability data or technique trials we have missed should write to standards@compoundjournal.com. This is one of the files where we would most like to be corrected, because the current state is that millions of injections a week are being given on the basis of transferred evidence and a four-line calculation.

Our practical conclusion is that the useful defences here are structural rather than attitudinal. Write the concentration on the vial. Recalculate at every new vial. Keep one syringe type. Change one variable at a time. Exhortations to be careful do not survive a bad week; a number written in marker on a piece of tape does.